US Patent Application 18248291. TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE simplified abstract
TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE
Organization Name
The Regents of the University of California
Inventor(s)
Yoshihiro Izumiya of Elk Grove CA (US)
Michiko Shimoda of Sacramento CA (US)
TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE - A simplified explanation of the abstract
This abstract first appeared for US patent application 18248291 titled 'TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE
Simplified Explanation
- The patent application describes a new invention that involves compositions and methods for treating diseases characterized by excessive cell proliferation, inflammatory conditions, or autoimmune diseases. - The invention focuses on inhibiting the activity of a protein called MYC in cells, particularly in MYC-dependent cancer cells. - The purpose of inhibiting MYC activity is to effectively treat the mentioned diseases. - The invention provides a novel approach to target MYC activity, which may lead to more effective treatments for diseases involving excessive cell proliferation, inflammation, or autoimmunity.
Original Abstract Submitted
The present invention provides compositions and methods for treating a disease involving inappropriate or excessive cell proliferation or for treating an inflammatory condition or an autoimmune disease by inhibiting MYC activity in cells such as MYC-dependent cancer cells.